Abstract
Twenty-three cocaine-dependent participants were randomly assigned to receive either dehydroepiandrosterone (DHEA; n = 11; 100 mg/day) or placebo (n = 12) in the context of 12 weeks of thrice weekly cognitive-behavioral group counseling. Outcomes were retention, urine drug screening, cocaine craving, adverse experiences, and medication compliance. DHEA-treated participants averaged 45.8 (SD = 28.8) days in treatment, compared with 70.7 (SD = 20.6) days for placebo, t(21) = -2.4, p = .03, and provided 26.8% (SD = 29.3) of urine samples free of cocaine metabolite compared with 70.6% (SD = 39.9) for the placebo condition, t(21) = -3.0, p = .01. No differences were detected between conditions for cocaine craving or adverse experiences. High levels of medication compliance were documented. Results argue against using high doses of DHEA as a pharmacotherapy for cocaine dependence.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 126-135 |
| Number of pages | 10 |
| Journal | Experimental and Clinical Psychopharmacology |
| Volume | 12 |
| Issue number | 2 |
| DOIs | |
| State | Published - May 2004 |
Fingerprint
ASJC Scopus subject areas
- Pharmacology
- Experimental and Cognitive Psychology
Cite this
Participants Receiving Dehydroepiandrosterone during Treatment for Cocaine Dependence Show High Rates of Cocaine Use in a Placebo-Controlled Pilot Study. / Shoptaw, Steve; Wilkins, Jeffery; Twitchell, Geoffrey; Majewska, Maria Dorota; Yang, Xiaowei; Ling, Walter.
In: Experimental and Clinical Psychopharmacology, Vol. 12, No. 2, 05.2004, p. 126-135.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Participants Receiving Dehydroepiandrosterone during Treatment for Cocaine Dependence Show High Rates of Cocaine Use in a Placebo-Controlled Pilot Study
AU - Shoptaw, Steve
AU - Wilkins, Jeffery
AU - Twitchell, Geoffrey
AU - Majewska, Maria Dorota
AU - Yang, Xiaowei
AU - Ling, Walter
PY - 2004/5
Y1 - 2004/5
N2 - Twenty-three cocaine-dependent participants were randomly assigned to receive either dehydroepiandrosterone (DHEA; n = 11; 100 mg/day) or placebo (n = 12) in the context of 12 weeks of thrice weekly cognitive-behavioral group counseling. Outcomes were retention, urine drug screening, cocaine craving, adverse experiences, and medication compliance. DHEA-treated participants averaged 45.8 (SD = 28.8) days in treatment, compared with 70.7 (SD = 20.6) days for placebo, t(21) = -2.4, p = .03, and provided 26.8% (SD = 29.3) of urine samples free of cocaine metabolite compared with 70.6% (SD = 39.9) for the placebo condition, t(21) = -3.0, p = .01. No differences were detected between conditions for cocaine craving or adverse experiences. High levels of medication compliance were documented. Results argue against using high doses of DHEA as a pharmacotherapy for cocaine dependence.
AB - Twenty-three cocaine-dependent participants were randomly assigned to receive either dehydroepiandrosterone (DHEA; n = 11; 100 mg/day) or placebo (n = 12) in the context of 12 weeks of thrice weekly cognitive-behavioral group counseling. Outcomes were retention, urine drug screening, cocaine craving, adverse experiences, and medication compliance. DHEA-treated participants averaged 45.8 (SD = 28.8) days in treatment, compared with 70.7 (SD = 20.6) days for placebo, t(21) = -2.4, p = .03, and provided 26.8% (SD = 29.3) of urine samples free of cocaine metabolite compared with 70.6% (SD = 39.9) for the placebo condition, t(21) = -3.0, p = .01. No differences were detected between conditions for cocaine craving or adverse experiences. High levels of medication compliance were documented. Results argue against using high doses of DHEA as a pharmacotherapy for cocaine dependence.
UR - http://www.scopus.com/inward/record.url?scp=2342421523&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=2342421523&partnerID=8YFLogxK
U2 - 10.1037/1064-1297.12.2.126
DO - 10.1037/1064-1297.12.2.126
M3 - Article
VL - 12
SP - 126
EP - 135
JO - Experimental and Clinical Psychopharmacology
JF - Experimental and Clinical Psychopharmacology
SN - 1064-1297
IS - 2
ER -